MedTrace Logo

BNP Measurement Reduces Resource Utilization for Patients With CHF Admitted Thorough the ED

NCT00587938 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2008-01-08

No results posted yet for this study

Summary

Measurement of brain natriuretic peptide (BNP) in dyspneic patients increases diagnostic accuracy for congestive heart failure (CHF). Limited information is available regarding economic outcomes attributable to BNP assay. The aim of this study was to assess the economic impact of BNP assay in elderly dyspneic patients presenting to the emergency department (ED).

Conditions

  • Congestive Heart Failure

Sponsors & Collaborators

Principal Investigators

  • Raquel M Schears, MD, MPH · Mayo Clinic

  • Alfredo L Clavell, MD · Mayo Clinic

  • Lyle J Olsen, MD · Mayo Clinic

  • Paula J Santrach, MD · Mayo Clinic

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2005-03-31
Completion
2005-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00587938 on ClinicalTrials.gov